Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
Protein Name: | MLLT3 |
Gene Name: | MLLT3 |
Protein Full Name: | Protein AF-9 |
Alias: | AF9; AF-9; ALL1 fused gene from chromosome 9; Myeloid/lymphoid or mixed-lineage leukemia (trithorax (Drosophila); Myeloid/lymphoid or mixed-lineage leukemia (trithorax homologue, Drosophila); Myeloid/lymphoid or mixed-lineage leukemia translocated to chromosome 3; Translocated to, 3 (AF9); YEATS domain-containing 3; YEATS3 |
Mass (Da): | 63351 |
Number AA: | 568 |
UniProt ID: | P42568 |
Locus ID: | 4300 |
COSMIC ID: | MLLT3 |
Gene location on chromosome: | 9p22 |
Cancer protein type: | OP |
Effect of cancer mutation on protein: | GAIN |
Effect of active protein on cancer: | PROMOTES |
Number of cancer specimens: | 20239 |
Percent of cancer specimens with mutations: | 0.84 |
Deregulated in translocations: | Translocation t(9;11) (p22;q23)-->MLL -AF9 in ANLL |
Normal role description: | MLLT3 is a transcriptional activator, and translocations of the gene with AF9 have been found in M5/M4 de novo- and therapy related ANLL. |
Commentary on involvement of protein in cancer: | 2/145 lung- and 1/59 ovarian cancer samples were mutated (Mis-sense) (Sanger COSMIC) |